期刊文献+

血清新喋呤与冠心病患者病变程度的关系 被引量:3

下载PDF
导出
摘要 目的探讨冠心病(CHD)病患血清新喋呤水平改变的临床评价。方法选择该院2012年1月至2013年6月收治的106例CHD患者,其中急性心肌梗死(AMI)组29例,不稳定型心绞痛(UAP)组40例,稳定型心绞痛(SAP)组37例,另选取同期30例冠状动脉造影显示为正常者作对照组。采用酶联免疫吸附法(ELISA)测定各组血清新喋呤的水平。结果 AMI组和UAP组病患的血清新喋呤水平为(11.85±2.30)nmol/L和(9.94±1.91)nmol/L,显著高于SAP组和对照组的(8.13±2.10)nmol/L、(7.97±1.99)nmol/L(均P<0.05);但AMI组与UAP组的血清新喋呤水平比较无统计学差异(P>0.05);SAP组与对照组之间的血清新喋呤水平比较无统计学差异(P>0.05)。单支病变组、双支病变组和三支病变组病患血清新喋呤水平分别为(9.89±1.28)nmol/L、(10.07±1.81)nmol/L、(9.93±1.91)nmol/L,均显著高于对照组的(7.97±1.99)nmol/L(均P<0.05),但不同冠状动脉病变支数组间比较差异无统计学意义(P>0.05)。Ⅰ型、Ⅱ型、Ⅲ型斑块组血清新喋呤的水平分别为(8.01±1.18)nmol/L、(10.97±2.81)nmol/L、(8.33±2.01)nmol/L,均显著高于对照组的(7.97±1.99)nmol/L(均P<0.05),Ⅱ型斑块组血清新喋呤的水平为(10.97±2.81)nmol/L,显著高于Ⅰ型、Ⅲ型斑块组的(8.01±1.18)nmol/L与(10.97±2.81)nmol/L(均P<0.05),Ⅰ型与Ⅲ型斑块组血清新喋呤的水平比较无统计学差异(P>0.05)。结论 CHD病患血清新喋呤的水平异常升高,病患血清新喋呤的水平与斑块形态有关,与冠状动脉病变支数无关,血清新喋呤的水平可以作为预测不稳定型斑块病变的辅助指标。
出处 《中国老年学杂志》 CAS CSCD 北大核心 2014年第9期2428-2429,共3页 Chinese Journal of Gerontology
  • 相关文献

参考文献7

  • 1Johann Auer,Robert Berent,Elisabeth Lassnig,Thomas Weber,Bernd Eber.Prognostic significance of immune activation after acute coronary syndromes[J].Journal of the American College of Cardiology.2002(11)
  • 2Emmanouil Zouridakis,Pablo Avanzas,Ramón Arroyo-Espliguero,Salim Fredericks,Juan Carlos Kaski.Markers of Inflammation and Rapid Coronary Artery Disease Progression in Patients With Stable Angina Pectoris[J].Circulation.2004(13)
  • 3宋尚明,刘同宝,陈良华.新喋呤与动脉粥样硬化及冠心病[J].临床心血管病杂志,2002,18(9):474-475. 被引量:9
  • 4Hans Martin Hoffmeister,Raila Ehlers,Evi Büttcher,Silke Kazmaier,Sebastian Szabo,Martin E Beyer,Armin Steinmetz,Ludger Seipel.Comparison of C-reactive protein and terminal complement complex in patients with unstable angina pectoris versus stable angina pectoris[J].The American Journal of Cardiology.2002(8)
  • 5郑高,郭飞州.心力衰竭患者血清新喋呤水平与心功能的关系探讨[J].现代实用医学,2012,24(1):31-32. 被引量:1
  • 6Salvatore De Rosa,Plinio Cirillo,Mario Pacileo,Gianluca Petrillo,Greta-Luana D’Ascoli,Fabio Maresca,Francesca Ziviello,Massimo Chiariello.Neopterin: From Forgotten Biomarker to Leading Actor in Cardiovascular Pathophysiology[J].Current Vascular Pharmacology.2011(2)
  • 7韩瑞梅,李杰,赵阳.不同性别急性ST段抬高性心肌梗死患者血尿酸水平分析[J].中国实用医刊,2011,38(19):14-15. 被引量:2

二级参考文献12

  • 1朱志军,黄元伟,任森根,胡中荣.冠心病免疫激活的一个指标—新蝶呤[J].中国心血管杂志,2005,10(1):31-32. 被引量:9
  • 2[1]Ross R. Atherosclerosis is an inflammatory disease. Am Heart J,1999,138(5 PT 2):S419-420.
  • 3[2]Weissberg P L.Atherosclerosis:Current understanding of the cause of atheroma. Heart, 2000,83(2):247-252.
  • 4[3]Schumacher M, Halwachs G, Tatzber F, et al. Increased neopterin in patients with chronic and acute coronary syndromes. J Am Coll Cardiol,1997,30(3):703-707.
  • 5[4]Gurfinkel E P, Scirica B M, Bozovich G, et al. Serum neopterin levels and the angiographic extent of coronary arterial narrowing in unstable angina pectoris and in non-Q-wave acute myocardial infarction. Am J Cardiol, 1999,83(4):515-518.
  • 6[5]Gupta S, Fredericks S, Schwartzman R A, et al. Serum meopterin in acute coronary syndromes. Lancet,1997,349(9060):1252-1253.
  • 7[6]Kashi J C. Increased neopterin in patients with chronic and acute coronary syndromes. J Am Coll Cardiol, 1998,31(5):1215-1216.
  • 8[7]Garcia-Moll X, Coccolo F, Cole D, et al. Serum neopterin and complex stenosis morphology in patients with unstable angina. J Am Cardiol, 2000,35(4):956-962.
  • 9[8]Garcia-Moll X, Cole D, Zouridakis E, et al. Increased serum neopterin: A marker of coronary arterial disease activity in women. Heart,2000,83(3):346-350.
  • 10Sasaki T,Takeishi Y,Suzuki S,et al.Highserum level of neopterin is a risk factor ofpatients with heart failure[J].Int J Cardiol,2010,19(2):145(2):318.

共引文献9

同被引文献27

  • 1陈虹,陈毓青,梁丽萍.冠状动脉易损斑块的药物治疗研究进展[J].中国全科医学,2013,16(8):946-948. 被引量:4
  • 2王丽芳,李永军,张晋霞,郝冀洪.血清新喋呤检测在重症急性胰腺炎患者中的价值[J].检验医学,2007,22(1):1-3. 被引量:3
  • 3GENSINI G G. A more meaningful scoring system for deter- mining the severity of coronary heart disease[J]. The Ameri can Journal of Cardiology, 1983,51 (3) :606.
  • 4FANTUZZI G, REED D A, DINARELLO C A. IL 12 in- duced IFNLgamma is dependent on caspase 1 processing of the IL-18 precursor[J]. The Journal of Clinical Investigation, 1999,104(6) :761- 767.
  • 5WOLDBAEK P R, TONNESSEN T, HENRIKSEN U 1., et al. Increased cardiac IL-18 mRNA, pro IL-18 and plasma IL 18 after myocardial infarction in the mouse; a potential role in cardiac dysfunction[J]. Cardiovascular Research, 2003,59 ( 1 ) : 122- 131.
  • 6VENKATACHALAM K, PRABHU S D, REDDY V S, et al. Neutralization of interleukin 18 ameliorates ischemia/reperfu sion induced myocardial injury[J]. The Journal of Biological Chemistry, 2009,284(12) :7853- 7865.
  • 7MALLAT Z, HENRY P, FRESSONNET R, et al. Increased plasma concentrations of interleukin-18 in acute coronary syn- dromes[J]. Heart (British Cardiac Society), 2002,88 (5) : 467- 469.
  • 8ADACHI T, NARUKO T, ITOH A, et al. Neopterin is asso- ciated with plaque inflammation and destahilisation in human coronary atherosclerotie lesions[J]. Heart (British Cardiac So- ciety), 2007,93(12) :1537-1541.
  • 9WEISS G, FUCHS D, HAUSEN A, et al. Neopterin modu- lates toxicity mediated by reactive Oxygen and chloride species [J]. FEBS Letters, 1993,321(1) :89 -92.
  • 10GIESEG S P, CRONE E M, FLAVALL E A, e1 al. Pmential to inhibit growth of atherosclerotic plaque development through modulation of macrophage neopterin/7,8-dihydrone- opterin synthesis[J].British Journal of Pharmacology, 2008, 153(4) :627-635.

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部